epomediol: marked choleretic activity in Wistar rats; mechanism of action may be related to increases in both the bile salt dependent & independent fractions of bile [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 115056 |
| CHEMBL ID | 3707255 |
| CHEBI ID | 81225 |
| SCHEMBL ID | 755885 |
| MeSH ID | M0098590 |
| Synonym |
|---|
| EU-0033557 |
| OPREA1_038830 |
| OPREA1_265120 |
| 1,8-epoxy-1-methyl-4-isopropylcyclohexane-2,6-diol |
| epomediol |
| clesidren |
| 1,3,3-trimethyl2-oxabicyclo(2.2.2)octane-6,7-diol |
| 2-oxabicyclo(2.2.2)octane-6,7-diol, 1,3,3-trimethyl- |
| 56084-15-2 |
| 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane-6,7-diol |
| 2,6-dihydroxycineol |
| C17620 |
| CHEBI:81225 |
| CHEMBL3707255 |
| SCHEMBL755885 |
| AKOS024356031 |
| 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane-6,7-diol # |
| 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane-6,7-endo,endo-diol |
| JSNQSLSBBZFGBM-UHFFFAOYSA-N |
| 2-oxabicyclo[2.2.2]octane-6,7-diol, 1,3,3-trimethyl- |
| 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octan-6,7-endo,endo,diol |
| exo,exo-1,8-epoxy-p-menthane-2,6-diol |
| sr-01000390393 |
| SR-01000390393-1 |
| exo,exo-form |
| FT-0726121 |
| Q5383801 |
| 1,8-epoxy-p-menthane-2,6-diol |
| DTXSID70971470 |
Epomediol (EPO) is a synthetic terpenoid compound shown to be active in increasing bile flow and some enzymatic activities of liver plasma membranes in the rat. It has been reported to reverse 17alpha-ethinyloestradiol-induced cholestasis and to have a choleretic effect related to the biliary secretion of epomediol glucuronide.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Epomediol is a terpenoid compound that has been reported to reverse 17alpha-ethinylestradiol-induced cholestasis and to have a choleretic effect related to the biliary secretion of epomediol glucuronide. " | ( Enhancement of bile acid pool size, synthesis and secretion by epomediol in the rat. Almar, M; Collado, PS; Cuevas, MJ; El-Mir, MY; Gonzalez-Gallego, J; Mauriz, JL, 2000) | 1.99 |
| "1. Epomediol is a terpenoid compound that has been reported to stimulate bile acid synthesis and to reverse 17alpha- ethinyloestradiol-induced cholestasis. " | ( Effect of epomediol on ethinyloestradiol-induced changes in bile acid and cholesterol metabolism in rats. Almar, M; Collado, PS; Cuevas, MJ; González-Gallego, J; Mauriz, JL, 2001) | 1.33 |
| "Epomediol is a synthetic terpenoid compound that has been reported to reduce ethinyloestradiol-induced cholestasis. " | ( Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat. Almar, M; Cuevas, MJ; González-Gallego, J, 2002) | 2.15 |
| "Epomediol is a terpenoid that prevents and reverses cholestasis induced by ethinylestradiol in the rat, apparently by improving liver cell membrane fluidity. " | ( [Symptomatic effect of epomediol in patients with cholestasis of pregnancy]. Andrighetti, F; Bianchi, M; González, M; Hernández, I; Iglesias, J; Molina, C; Reyes, H; Ribalta, J; Tiribelli, C, 1992) | 2.04 |
| "Epomediol (EPO) is a synthetic terpenoid compound shown to be active in increasing bile flow and some enzymatic activities of liver plasma membranes in the rat. " | ( Reversal of ethinylestradiol-induced cholestasis by epomediol in rat. The role of liver plasma-membrane fluidity. Corsi, R; Gazzin, B; Lunazzi, GC; Miccio, M; Orzes, N; Tiribelli, C, 1989) | 1.97 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Epomediol-treated rats had a 24% larger bile acid pool and 28% greater bile acid synthesis than controls when measured by the "washout" technique." | ( Enhancement of bile acid pool size, synthesis and secretion by epomediol in the rat. Almar, M; Collado, PS; Cuevas, MJ; El-Mir, MY; Gonzalez-Gallego, J; Mauriz, JL, 2000) | 1.27 |
| Class | Description |
|---|---|
| oxanes | Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 17 (68.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (24.14%) | 5.53% |
| Reviews | 1 (3.45%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (72.41%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||